Zenas BioPharma, Inc. — Form 8-K
Filed November 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Zenas BioPharma registered a $200 million at-the-market (ATM) offering of common stock via an Open Market Sale Agreement with Jefferies LLC, dated October 8, 2025. The Registration Statement on Form S-3ASR became effective October 8, 2025; this supplemental legal opinion was delivered November 6, 2026, accompanying the prospectus supplement filing under Rule 424. The offering allows the company to sell up to $200M of shares opportunistically at prevailing market prices.
Why this rating
ATM offering of $200M (~77% of company market cap) is material financing event, but routine capital-raise mechanism. Neutral impact absent guidance or strategic announcement; timing and pricing unknown.
Price action (we called it neutral)
before filing · preread $28.26 ▲ 0.00% | at our read · unknown $28.26 | +10 min · unknown $28.17 ▼ 0.32% | +30 min · unknown $28.48 ▲ 0.78% | +1 hr · unknown $29.33 ▲ 3.79% | +4 hrs · unknown $29.29 ▲ 3.63% |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.